Q-omics provides the consensus-scored SNX18P7 profile across patient tissues and cancer cell-line models. SNX18P7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNX18P7 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SNX18P7 RNA expression shows 13,667 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where SNX18P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX18P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX18P7 survival associations across molecular data types. SNX18P7 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX18P7 RNA expression–survival associations across cancer types. High SNX18P7 expression shows unfavorable associations in KIRC, MESO, STAD, ACC, COAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNX18P7 RNA expression.
This table summarizes SNX18P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNX18P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX18P7 shows lower tumor expression in THCA and KIRC and higher tumor expression in KIRP, LUSC, LUAD and HNSC. The THCA box plot shows higher SNX18P7 RNA expression in normal versus tumor tissue (log2 FC = −0.210, t-test p < 0.001).
This table shows molecular features associated with SNX18P7 in patient tissues and cancer cell lines. In patient samples, SNX18P7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
